Stay updated on Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Pancreatic Cancer Clinical Trial page
- ChecktodayChange DetectedThe screenshots show essentially the same study details page with no substantial edits to core content such as eligibility criteria, interventions, or outcomes; only minor UI/formatting differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check7 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a government-funding notice and updated the version to v3.2.0, while removing the old v3.1.0 version tag.SummaryDifference5%

- Check36 days agoChange DetectedUpdated to Revision: v3.1.0 with expanded contact emails/phone numbers; removed obsolete revision v3.0.2. No changes detected to pricing, stock, or time slots.SummaryDifference0.1%

- Check51 days agoChange DetectedUpdated Revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element. No other substantive changes detected.SummaryDifference0.3%

- Check58 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%

- Check65 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as new content related to Combined Modality Therapy and Neoadjuvant Therapy. Notably, the drug pembrolizumab has been both added and removed, indicating a potential update in its relevance or context.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.